drugset / Trial / NCT04676659

Summary

To explore the safe and efficacious dose of rhTNK-tPA injection administered within 3 hours after onset of hyperacute ischemic stroke; to provide dose evidence for phase III clinical trial.

Timeline

Start
2018-05-12
Primary completion
2020-05-30
Completion
2020-07-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Alteplase Protein / enzyme biologic 0.9 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.1 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.25 mg/kg Intravenous
Subject Tenecteplase Protein / enzyme biologic 0.32 mg/kg Intravenous

Indications